Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Plummer

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Forensic Science International|November 6, 2018
Analysis of elemental and isotopic variation in glass frictionators from 0.22 rimfire primersKelsey E Seyfang, Hilton J Kobus, Rachel S Popelka-Filcoff, et al.
Emerging Infectious Diseases|December 25, 2012
Novel framework for assessing epidemiologic effects of influenza epidemics and pandemicsCarrie Reed, Matthew Biggerstaff, Lyn Finelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 23, 2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 resultsJürgen K Rockstroh, Edwin DeJesus, Keith Henry, et al.
Pediatric Emergency Care|February 22, 2013
Mass screening for fever in children: a comparison of 3 infrared thermal detection systemsMonica U Selent, Noelleangelique M Molinari, Amy Baxter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 22, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsDavid A Wohl, Calvin Cohen, Joel E Gallant, et al.
AIDS (London, England)|February 10, 2018
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trialsKirsten White, Will Garner, Lilian Wei, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. Infectious Diseases|November 6, 2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority studyAnthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Forensic Science International|November 6, 2018
Analysis of elemental and isotopic variation in glass frictionators from 0.22 rimfire primersKelsey E Seyfang, Hilton J Kobus, Rachel S Popelka-Filcoff, et al.
Emerging Infectious Diseases|December 25, 2012
Novel framework for assessing epidemiologic effects of influenza epidemics and pandemicsCarrie Reed, Matthew Biggerstaff, Lyn Finelli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 23, 2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 resultsJürgen K Rockstroh, Edwin DeJesus, Keith Henry, et al.
Pediatric Emergency Care|February 22, 2013
Mass screening for fever in children: a comparison of 3 infrared thermal detection systemsMonica U Selent, Noelleangelique M Molinari, Amy Baxter, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsAndrew Zolopa, Paul E Sax, Edwin DeJesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 22, 2013
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 resultsDavid A Wohl, Calvin Cohen, Joel E Gallant, et al.
AIDS (London, England)|February 10, 2018
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trialsKirsten White, Will Garner, Lilian Wei, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. Infectious Diseases|November 6, 2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority studyAnthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, et al.
Pageof 3